	US 12,435,036 B2
	Salts and solid forms of (R)-1-(5-methoxy-1H-indol-1-yl)-n,n-dimethylpropan-2-amine
Matthew Duncton, Las Vegas, NV (US); and Samuel Clark, Miami, FL (US)
Assigned to Terran Biosciences Inc., Miami Beach, FL (US)
Filed by Terran Biosciences Inc., Miami Beach, FL (US)
Filed on May 16, 2024, as Appl. No. 18/666,109.
Application 18/666,109 is a continuation of application No. 18/177,408, filed on Mar. 2, 2023.
Application 18/177,408 is a continuation of application No. 17/988,753, filed on Nov. 16, 2022, abandoned.
Claims priority of provisional application 63/319,735, filed on Mar. 14, 2022.
Claims priority of provisional application 63/316,924, filed on Mar. 4, 2022.
Claims priority of provisional application 63/310,977, filed on Feb. 16, 2022.
Claims priority of provisional application 63/280,084, filed on Nov. 16, 2021.
Claims priority of provisional application 63/280,085, filed on Nov. 16, 2021.
Prior Publication US 2025/0002456 A1, Jan. 2, 2025
Int. Cl. C07D 209/08 (2006.01)

CPC C07D 209/08 (2013.01) [C07B 2200/13 (2013.01)]

14 Claims

1. A crystalline (R)-1-(5-methoxy-1H-indol-1-yl)-N,N-dimethylpropan-2-amine, (compound 1) salt, wherein the salt is selected from:

(i) a HCl salt;

(ii) a maleate salt;

(iii) a benzoate salt;

(iv) a tosylate salt;

(v) a tartrate salt;

(vi) a HBr salt;

(vii) a galactarate salt;

(viii) a succinate salt;

(ix) a citrate salt;

(x) a malate salt;

(xi) a glucuronate salt;

(xii) an ascorbate salt;

(xiii) a sulfate salt

(xiv) a mesylate salt;

(XV) an esylate salt;

(xvi) a phosphate salt;

(xvii) an edisylate salt; and

(xviii) an adipate salt.